Unique Perspective: Cancer Biologist & Pet Cancer Parent

Dr. Elizabeth Iorns is a scientist whose research focuses on identifying mechanisms of breast cancer progression. She is a cofounder and CEO of Science Exchange, and she helped launch the Reproducibility Initiative. She was involved in the development of Olaparib, a targeted therapy directed at the BRCA1 and BRCA2 mutation, best known for its relation […]

Medical Brief: Sorafenib in Dogs

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs. By Laura Marconato, et al(Cancers (Basel). 2020 May 18;12(5):1272. doi: 10.3390/cancers12051272).

Rising Women in Veterinary Oncology

An introduction from Chief Medical Officer, Dr. Gerry Post Veterinary medicine is changing. I remember one of my first days in veterinary school looking at the class pictures that were hung in the hallways. I remember seeing the first woman in one of these class photos and noting that she was still practicing.

World Veterinary Day Interview: Strengthening Veterinary Resilience

Resilience is defined as the capacity to recover quickly from difficulties and toughness– there are both physical and psychological resilience. Both have been severely tested these last few years with the pandemic, the current war, national divisions, etc. and have really affected veterinarians in the world at large.

Personalized Medicine: Because Not All Tumors Are Created Equally

With new research and medical advancements, immunotherapy is the new frontier in veterinary oncology. Please join us in welcoming Dr. Nicola Mason, B.Vet.Med, PhD, DACVIM (Internal Medicine), Professor of Medicine & Pathobiology at the University of Pennsylvania School of Veterinary Medicine. She is an innovator in veterinary immunology, leading clinical studies and research laboratories investigating […]

Literature Support for Targeted Therapy

In recent academic literature, there have been more and more publications documenting that biochemical pathways in canine cancer cells are often dysregulated, and therefore, targeted therapies are likely of value.